Silence Therapeutics (SLN) Accumulated Depreciation & Amortization (2023 - 2025)

Silence Therapeutics' Accumulated Depreciation & Amortization history runs 3 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation & Amortization fell 12.46% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (down 12.46% YoY), while the FY2025 annual figure was $4.0 million, down 12.46% from the prior year.
• Accumulated Depreciation & Amortization came in at $4.0 million for Q4 2025 at Silence Therapeutics, down from $4.5 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $4.5 million in Q4 2024 to a low of $4.0 million in Q4 2025.
• A 3-year average of $4.2 million and a median of $4.2 million in 2023 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization advanced 8.1% in 2024 and declined 12.46% in 2025, its largest moves.
• Silence Therapeutics' Accumulated Depreciation & Amortization stood at $4.2 million in 2023, then climbed by 8.1% to $4.5 million in 2024, then retreated by 12.46% to $4.0 million in 2025.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $4.0 million, $4.5 million, and $4.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison